Table 2.
Clinical and pathologic data
| Clinical Features | MBCB | PBC | |
|---|---|---|---|
| (n =16) | (n = 64) | ||
| ER | Negative | 6.25% (1/16) | 14% (9/64) |
| Positive | 93.75% (15/16) | 86% (55/64) | |
| PgR | Negative | 12.5% (2/16) | 22% (14/64) |
| Positive | 81.25% (13/16) | 78% (50/64) | |
| Unknown | 6.25% (1/16) | 0% (0/64) | |
| HER2 | Negative | 50% (8/16) | 91% (58/64) |
| Positive | 18.75% (3/16) | 9% (6/64) | |
| Equivocal | 18.75% (3/16) | 0% (0/64) | |
| Unknown | 12.5% (2/16) | 0% (0/64) | |
| BR | Rapid | 43.75% (7/16) | N/A |
| Slow | 56.25% (9/16) | N/A | |
| Type | Ductal | 87.5% (14/16) | 81.25% (52/64) |
| Lobular | 6.25% (1/16) | 14% (9/64) | |
| Mixed | 6.25% (1/16) | 3% (2/64) | |
| Metaplastic | 0% (0/16) | 1.55% (1/64) | |
| Node status | Positive | 50% (8/16) | 40.6% (26/64) |
| Negative | 50% (8/16) | 53.2% (34/64) | |
| Unknown | 0% (0/16) | 6.2% (4/64) | |
| Tumor size | <2 cm | 25% (4/16) | 57.8% (37/64) |
| >2 cm | 50% (8/16) | 29.7% (19/64) | |
| >5 cm | 18.75% (3/16) | 10.9% ('7/64) | |
| Unknown | 6.25% (1/16) | 1.6% (1/64) | |
ER indicates estrogen receptor; PgR progesterone receptor; BR bone relapse.